Slovak
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
antirheumatics/zhubný nádor
Odkaz sa uloží do schránky
Strana 1 od 75 výsledky
Immunoassay and Regulation of Traditional Chinese Medicine on Cancer Patients
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
Traditional Chinese medicine (TCM) and dendritic cells (DCs) activation/maturation One of the important approaches to successful cancer immunotherapy is generation of specific T cell responses by dendritic cells (DCs). DCs are the most potent antigen-presenting cells for naive T cells, because their
Spondyloarthritis: Inducing Drug-free Remission by Early TNF-alpha Blockade
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
SPARTACUS will have several achievable goals:
1. To show superiority of early treatment of pSpA patients with bDMARDs as compared to standard of care.
In current practice, TNFi, the predominant bDMARDs in SpA, are only reimbursed in a restricted number of indications: they can be prescribed for
Socio-economic Determinants for Acceptance and Choice of Biological Treatment
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
This was a cross-sectional observational study conducted in the rheumatology clinic of National Center for Rheumatic Diseases, Kathmandu, Nepal. Patients with spondyloarthropathy (SpA) and enrolled in the cohort database from June 2015 to December 2019 were selected. Those taking any oral or
Using Adalimumab Serum Concentration to Choose a Subsequent Biological DMARD in Rheumatoid Arthritis Patients Failing Adalimumab Treatment
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
Over the last decades biopharmaceuticals such as agents against tumor necrosis factor (TNF), are frequently prescribed to optimize rheumatoid arthritis treatment. Although TNFi such as adalimumab, etanercept and infliximab, have improved the treatment of rheumatoid arthritis, a proportion of
Treat-to-target Strategy in Ankylosing Spondylitis Using Etanercept and Conventional Synthetic DMARDs
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
The tumor necrosis factor inhibitors(TNFi) like etanercept(ETN) has been always recommended as the primary treatment option for active AS. But when sustained applied in daily clinical practices, it is unaffordable for patients in developing countries in most cases due to the high expense of TNFi. On
Golimumab in Juvenile Idiopathic Arthritis-associated Uveitis Failing Adalimumab
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
Background:
Uveitis is a potentially blinding complication of juvenile idiopathic arthritis (JIA). Treatment remains a substantial challenge, even though the use of tumor necrosis factor (TNF)-α-antagonists has improved visual outcomes substantially. Among these agents, adalimumab has been recently
Advanced Therapeutics in Rheumatoid Arthritis (RA)
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
Conventional therapies for Rheumatoid Arthritis (RA) treatment include nonsteroidal anti-inflammatory drugs (NSAIDs), cyclooxygenase-2 (COX-2) selective inhibitors, corticosteroids and disease modifying anti-rheumatic drugs (DMARDs). These therapies are often partially effective.
For those patients,
Metformin Use in Rheumatoid Arthritis
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
Abatacept and the Risk of Cancer: a Case Non-case Analysis in VigiBase
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
A case non-case study using Vigibase®, the World Health Organization Global Individual Case Safety Reports (ICSRs) database which includes more than 18 million reports forwarded to the WHO Uppsala Monitoring Center by national pharmacovigilance systems from over 130 countries around the world since
Cognitive Behavioural Therapy for Insomnia on Sleep in Rheumatoid Arthritis.
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
Introduction:
More than half of patients with rheumatoid arthritis has concomitant insomnia. Insomnia may modify pain, fatigue, quality of life and comorbidities which many patients struggle with. To address this issue, a nurse led sleep outpatient clinic was established in 2015 at the Center for
Severe Psoriatic Arthritis - Early intervEntion to Control Disease: the SPEED Trial
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
Arm 1: Control 'step-up' therapy in the cohort (MONITOR-PsA study). Therapy for the cohort is defined by standard practice in these PsA clinics following current international recommendations[11] and National requirements for the prescription of biologic therapy[19-22]. Whilst physician discretion
PsA Secukinumab XCT Structural Progression Study
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
Psoriatic arthritis (PsA) is a chronic inflammatory joint disease associated with psoriasis. PsA is associated with distinctive clinical features including changes in skin and nails, peripheral arthritis, axial disease, dactylitis and enthesitis. Synovial inflammation in peripheral joints is the
The Immunogenicity and Safety of Zostavax® in Rheumatoid Arthritis Patients Using Abatacept
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
Recently, a live-attenuated vaccine (Zostavax®, Merck) to prevent herpes zoster (HZ) has been developed and approved for use among individuals age 50 years or older, regardless of previous HZ or varicella history. In a pivotal study of 38,456 older adults led by Dr. Michael Oxman (a co-investigator
Rotation or Change of Biotherapy After TNF Blocker Treatment Failure for Axial Spondyloarthritis
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
Effect of Sarilumab on Patient-reported Outcomes in Patients With Active Rheumatoid Arthritis
Články môžu prekladať iba registrovaní používatelia
Prihlásiť Registrácia
The study duration per patient is expected to be approximately 32 weeks, with up to 4-week screening, 24 weeks treatment, and 2-4 weeks post-treatment observations.
Najkompletnejšia databáza liečivých bylín podporovaná vedou
- Pracuje v 55 jazykoch
- Bylinné lieky podporené vedou
- Rozpoznávanie bylín podľa obrázka
- Interaktívna GPS mapa - označte byliny na mieste (už čoskoro)
- Prečítajte si vedecké publikácie týkajúce sa vášho hľadania
- Vyhľadajte liečivé byliny podľa ich účinkov
- Usporiadajte svoje záujmy a držte krok s novinkami, klinickými skúškami a patentmi
Zadajte príznak alebo chorobu a prečítajte si o bylinách, ktoré by vám mohli pomôcť, napíšte bylinu a pozrite sa na choroby a príznaky, proti ktorým sa používa.
* Všetky informácie sú založené na publikovanom vedeckom výskume
